Press release, Helsinki, 20 November 2023 at 11 AM (EET)
Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) announces having received an NBS System 6 order from a hospital in Massachusetts, United States.
Nexstim released the NBS 6 in the spring of 2023 and announced first order for the system on November 14. The NBS System 6 is a new generation system that makes Nexstim’s established TMS technology even more intuitive to use and allows for an expansion of system capabilities over time. Currently FDA approved for the treatment of major depressive disorder (MDD), the system has been created to answer to the needs of Nexstim’s current and potential customers. More information on the NBS System 6 is available on Nexstim’s website at https://www.nexstim.com/healthcare-professionals/nbs-6.
Mikko Karvinen, CEO of Nexstim, comments: “We are happy to announce having received our second NBS System 6 order within a week from our first order. Our client base consists of both private clinics and hospitals, and this order demonstrates the interest in our new product from both customer groups. We find ourselves in a good position to continue our important expansion both in the US hospitals and clinics for the end of 2023 and our strategy period that extends to 2024.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com